

General Certificate of Education June 2010

Biology BIOL1

Biology and disease

Final

Mark Scheme

Mark schemes are prepared by the Principal Examiner and considered, together with the relevant questions, by a panel of subject teachers. This mark scheme includes any amendments made at the standardisation meeting attended by all examiners and is the scheme which was used by them in this examination. The standardisation meeting ensures that the mark scheme covers the candidates' responses to questions and that every examiner understands and applies it in the same correct way. As preparation for the standardisation meeting each examiner analyses a number of candidates' scripts: alternative answers not already covered by the mark scheme are discussed at the meeting and legislated for. If, after this meeting, examiners encounter unusual answers which have not been discussed at the meeting they are required to refer these to the Principal Examiner.

It must be stressed that a mark scheme is a working document, in many cases further developed and expanded on the basis of candidates' reactions to a particular paper. Assumptions about future mark schemes on the basis of one year's document should be avoided; whilst the guiding principles of assessment remain constant, details will change, depending on the content of a particular examination paper.

Further copies of this Mark Scheme are available to download from the AQA Website: www.aqa.org.uk

Copyright © 2010 AQA and its licensors. All rights reserved.

COPYRIGHT

AQA retains the copyright on all its publications. However, registered centres for AQA are permitted to copy material from this booklet for their own internal use, with the following important exception: AQA cannot give permission to centres to photocopy any material that is acknowledged to a third party even for internal use within the centre.

Set and published by the Assessment and Qualifications Alliance.

Although specific marks are not awarded in question 1-7, marks will take into account the quality of written communication. Credit will only be awarded where candidates have presented information clearly and coherently and have used the specialist vocabulary indicated in the mark scheme for this unit. Specific references to the quality of written communication are marked **Q** in this mark scheme.

| Question | Marking guidance | Mark | Comments |
|----------|---|-------|--|
| 1(a) | Capsule / glycocalyx / slime layer; | 3 max | Q Reject: capsid |
| | Circular / ring of / non-linear DNA / DNA without histones; | | Neutral: slime |
| | Plasmid; | | Neutral: mesosome |
| | Flagellum; | | Accept: cell wall if qualified as murein / peptidoglyclan |
| | Pilus; | | Neutral: structures absent from prokaryotes |
| | Small / less dense / 70s ribosomes; | | |
| 1(b) | Lower / more negative <u>water potential</u> (in lumen / intestine / gut); | 2 | Q Use of correct terminology. Do not credit references to 'water concentration'. |
| | Water enters (intestine) / leaves (body) cells by osmosis; | | Neutral: hypertonic instead of lower water potential |
| | | | Neutral: water does not leave lumen by osmosis |
| | | | Must be in the correct context. |
| 1(c)(i) | Kills / destroys bacteria; | 1 | Q Do not allow 'kills germs' |
| | OR | | Accept: microorganisms / pathogens / examples |
| | Does not contain bacteria / removes bacteria / sterile / prevents bacteria entering body; | | Neutral: denatures bacterial enzymes |
| | prevents bacteria entering body, | | Neutral: to make it easier to dissolve the powder |
| | | | Reject: denatures bacteria / kills toxins |

| 1(c)(ii) | Sodium (ions) / potassium (ions) / chloride (ions) / citrate (ions); | 1 | Q Reject: chlorine |
|----------|--|---|--------------------------------|
| | (iono), | | Neutral: salts |
| | | | Accept: chlorine ions |
| | | | Accept: sodium chloride / salt |
| | | | Neutral: water |
| | | | Neutral: amino acids |

| Question | Marking guidance | Mark | Comments |
|----------|--|-------|---|
| 2(a)(i) | (Lung volume) increases / reaches a maximum (at B); | 1 | Do not negate mark for 'breathing out' if qualified e.g. when (lung volume) decreases |
| 2(a)(ii) | Flattens / lowers / moves down; | 2 | |
| | (Diaphragm / muscle) contracts; | | Reject: second mark only if intercostal muscles cause the diaphragm to flatten |
| 2(b) | Pulmonary ventilation = tidal volume × breathing rate; | 3 max | Accept: ventilation rate instead of breathing rate |
| | Breathing rate increases / more breaths per min (between C and D) / peaks get closer; | | Neutral: breathing increases Accept: breathe quicker |
| | <u>Tidal volume</u> / volume of air (inhaled) <u>per breath</u> increases (between C and D) / deeper breaths; | | Neutral: volume in lungs increases |
| | | | Accept: distance from bottom to top of peak increases |
| | (<u>Tidal volume</u> increase) qualified by data from graph e.g. approximate three-fold increase / appropriate | | for 'tidal volume increases' |
| | calculation; | | Neutral: higher peaks for 'tidal volume increases' |

| Question | Marking guidance | Mark | Comments |
|-----------|---|-------|--|
| 3(a) | Peptide; | 1 | Q Do not accept polypeptide Neutral: covalent |
| 3(b) | (F) H J E (K); | 2 | All three boxes correct = 2 marks Two boxes correct = 1 mark |
| 3(c) | (Site of aerobic) respiration; | 2 max | Q Reject: anaerobic respiration |
| | Release ATP / energy; | | Q Reject: produces / makes energy |
| | Active transport / transport against the concentration gradient / protein synthesis / exocytosis; | | Accept: produces ATP for energy |
| | , protein synancial and systems, | | Reject: produces ATP for respiration |
| | | | Neutral: protein secretion |
| 3(d)(i) | Breaks open cells / disrupts cell membrane / releases cell contents / releases organelles / break up cells; | 1 | Reject: breaks down cell wall |
| | contents / releases organishes / break up cells, | | Neutral: separates the cells |
| | | | Reject: breaks up cells so they can be separated |
| | | | Reject: breaks up / separates organelles |
| 3(d)(ii) | Removes (cell) debris / complete cells / tissue; | 1 | Neutral: to isolate organelle G / mitochondria |
| | | | Neutral: removes unwanted substances / impurities |
| | | | Reject: removes organelles / cell walls |
| 3(d)(iii) | Reduces / prevents <u>enzyme</u> activity; | 1 | Reject: ref. to denaturation |

| 3(d)(iv) | Prevents osmosis / no (net) movement of water / water does not enter organelle / water does not leave organelle; | 2 | Neutral: ref. to water potential |
|----------|--|---|---|
| | So organelle / named organelle is not damaged / does not burst / does not shrivel; | | Q Ref. to cells rather than organelles negates the second mark only |
| | | | Reject: ref. to turgid / flaccid for second mark |
| | | | Reject: organelle 'explodes' for second mark |

| Question | Marking guidance | Mark | Comments |
|----------|--|-------|--|
| 4(a) | (yes): Many women (with cervical cancer) have HPV 16 (18 &31); | 3 max | Neutral: correlation between HPV (16) and cervical cancer |
| | (no): Few women (with cervical cancer) have <u>HPV 6 /11;</u> | | Reject: many women with HPV 16 (18 &31) have cervical cancer / not all women have cancer |
| | (HPV infection does not mean causation because): Could be caused by another factor / example given / may be | | Accept: figures from graph for 'many' and 'few' |
| | due to coincidence; No control group / did not study HPV in healthy women / did | | Accept: minor errors in reading HPV frequencies from graph |
| | not study all HPV types / having cancer may increase susceptibility to HPV / does not add up to 100% / not all | | Reject: does not mean HPV vaccine causes cancer; |
| | women with cancer have HPV / individual may have more than one HPV type; | | Neutral: refs. to sample size and factors that should have been kept constant |
| 4(b)(i) | Protein / glycoprotein / glycolipid / polysaccharide; | 2 | |
| | Causes immune response / antibody production; | | Accept: B / T cell production |
| 4(b)(ii) | Memory cells produced / remain / stored (from previous infection); | 3 max | Neutral: antibodies produced / remain |
| | (When individual) comes into contact with virus / antigen (again); | | Neutral: 'cell' instead of 'virus' Reject: 'bacteria' once only |
| | Rapid / secondary / greater response / many or more antibodies produced; | | Accept: B cells / T cells |
| | Destroys virus / antigen before it can cause harm / symptoms / cancer; | | Reject: if destroys the virus / antigen in the vaccine before it can cause harm |
| | | | Q Do not allow 'fights HPV' |
| | | | Q Do not allow 'memory cells remember' |

| 4(c) | HPV destroyed in males / prevents males being carriers of HPV; | 2 | Neutral: prevents males catching HPV |
|------|---|---|--|
| | Prevents males passing on HPV (to unvaccinated females) / HPV may cause (other) cancers in males; | | Accept: reference to herd effect protecting the population |

| Question | Marking guidance | Mark | Comments |
|----------|---|-------|--|
| 5(a) | Active site; (Complementary / specific) structure / shape; (Only) fits / binds to gangliosides; Forms enzyme-substrate complexes; OR | 3 max | Note: 'active site has a specific shape' = 2 marks; Reject: same shape Second mark for either route can refer to the enzyme or the substrate |
| | Active site; (Complementary / specific) structure / shape; (Does not) fit / bind with other lipids; Does not form enzyme-substrate complexes; | | Accept: converse of second mark point and (different) structure / shape if referring to other lipids |
| 5(b)(i) | No change / substrate remains high / horizontal line; | 1 | Curve should be labelled If curve H correctly labelled then assume other is curve T |
| | | | Reject: obvious rise or fall / rise then plateau |
| 5(b)(ii) | Curve decreases rapidly at first then more slowly; | 1 | Curve should be labelled |
| | | | If curve T correctly labelled then assume other is curve H |
| | | | Reject: falling at a slower rate initially |
| 5(c) | (Enzymes are) proteins; Digested / broken down / destroyed (by enzymes / acid); | 2 | Accept: denatured (by acid) |
| | OR . | | Neutral: digested by saliva |
| | | | Reject: digested by amylase |
| | (Enzymes are) too large; To cross cell membranes / be absorbed / enter the bloodstream; | | Neutral: will not reach the bloodstream |

| Question | Marking guidance | Mark | Comments |
|----------|---|-------|--|
| 6(a) | Two suitable factors, e.g: Named dietary factor(s) / (cigarette) smoking / high blood pressure / gender / age / alcohol / genes / lack of exercise / obesity / stress; | 2 max | Neutral: cholesterol Accept: two different dietary factors for 2 marks e.g. LDL and salt Accept: LDL or fatty material Accept: ethnicity / race for 'genes' Accept: overweight for 'obesity' |
| 6(b)(i) | Healthy volunteers have 'normally' functioning vessels; OR | 1 | Accept: a valid ethical argument e.g. treatment does not harm healthy volunteers |
| | Blood vessel / lumen / diameter not affected by other factors / is of normal size; | | Reject: ref. to change in artery thickness Accept: converse arguments for unhealthy volunteers Must be related to this investigation Neutral: to ensure that that the results are due to the independent variable |
| 6(b)(ii) | Avoids bias / selection (by scientists); | 1 | Neutral: ref. to having the same number / gender / age of people in each group; |
| 6(c)(i) | Same as experimental group; Chocolate with no flavenoids; | 2 | Neutral: no dark chocolate Neutral: placebo Reject: milk chocolate Neutral: ref. to fair testing |

| 6(c)(ii) | (To ensure that results are) not due to some other substance in the chocolate / due to flavenoids (only); | 1 | Must be related to <i>this</i> investigation Neutral: to ensure that that the results are due to the independent variable Neutral: to show results are not due to other factors |
|----------|---|-------|---|
| | | | Neutral: to show results are only due to the chocolate Neutral: to compare results for people who did and did not have flavenoids |
| 6(d) | Coronary artery also likely to have a wide lumen; | 3 max | |
| | (Less chance of) high blood pressure; | | Accept: reduces blood pressure |
| | (Less chance of) a blood clot / thrombosis; | | Neutral: (less chance of) a blockage |
| | (Less chance of) atheroma / description given; | | |

| Question | Marki | ng guidance | Mark | Comments |
|----------|-------|---|-------|--|
| 7(a) | 1 | (Simple / facilitated) <u>diffusion</u> from high to low concentration / down <u>concentration gradient;</u> | 5 max | Q Do not allow across / along / with concentration gradient |
| | 2 | Small / non-polar / lipid-soluble molecules pass via phospholipids / bilayer; | | Reject: named molecule passing through membrane by an incorrect route for point 2 |
| | | OR | | Accept: diagrams if annotated |
| | | Large / polar / water-soluble molecules go through proteins; | | |
| | 3 | Water moves by osmosis / from high water potential to low water potential / from less to more negative water potential; | | |
| | 4 | Active transport is movement from low to high concentration / against concentration gradient; | | Only penalise <u>once</u> if active transport is not named in point 4. e.g. 'movement against the concentration gradient involves proteins and requires ATP' = 2 marks |
| | 5 | Active transport / <u>facilitated diffusion</u> involves proteins / carriers; | | Accept: facilitated diffusion involves channels for point 5 |
| | 6 | Active transport requires energy / ATP; | | Reject: active transport involves channels for point 5 |
| | 7 | Ref. to Na ⁺ / glucose co-transport; | | Credit ref. to endo/exocytosis as an alternative to point 7 |

| 7(b) | 1 | Many alveoli / alveoli walls folded provide a large surface area; | 5 max | Neutral: alveoli provide a large surface area |
|------|----|---|-------|--|
| | 2 | Many capillaries provide a large surface area; | | Neutral: greater / better diffusion Neutral: fast gas exchange |
| | 3 | (So) fast <u>diffusion;</u> | | Allow 'fast diffusion' only once |
| | 4 | Alveoli or capillary walls / epithelium / lining are thin / short distance between alveoli and blood; | | Reject: thin membranes / cell walls Accept: one cell thick for 'thin' |
| | 5 | Flattened / squamous epithelium; | | Accept: endothelial |
| | 6 | (So) short diffusion distance / pathway; | | |
| | 7 | (So) fast <u>diffusion;</u> | | |
| | 8 | Ventilation / circulation; | | Accept: descriptions for ventilation / circulation |
| | 9 | Maintains a diffusion / concentration gradient; | | Do not double penalise if description lacks detail e.g. thin membranes so a short diffusion distance |
| | 10 | (So) fast <u>diffusion;</u> | | = 1 mark |